IL17A and Miyoshi myopathy: In addition, groups undergoing active treatment management (both the Dexamethasone/Bortezomib and IMiDs group) displayed lower levels of IL-17 (p < 0.001 Figure 3A), glomerular filtration-rate (p < 0.001 Figure 3B), and higher levels of MV (p < 0.001, Figure 3C) compared to the WW Smoldering MM group (Table 1).